Into the unknown: biotech’s quest to target the 'undruggable' proteome

Novel therapeutic modalities, such as PROTACs, allow access to formerly undruggable parts of the proteome, shifting the frontiers of drug discovery. Artificial intelligence-based target scoring algorithms can help biotechs prioritize disease-relevant proteins as modality tailored drug targets.